Receive the latest updates from Matrix Medical in real time to understand product information.

On July 29, 2022, Wang Wenxu, Vice Governor of Zhejiang Province, Chen Jin, Standing Committee Member and Deputy Mayor of Hangzhou Municipal Party Committee, Wang Qian, District Chief of Yuhang District, Xu Runlong, Director of Zhejiang Provincial Drug Administration, and Li Jie, Secretary and Director of the Party Working Committee of Future Science and Technology City Management Committee, led a delegation to visit Hangzhou Matrix Medical Technology Co., Ltd. and learn about the innovative development of medical devices.

Vice Governor Wang Wenxu and his delegation first listened to General Manager Ji Peihong's introduction on the development concept of innovative technology for vascular intervention medical devices for the future, as well as the company's current research and development achievements and strategic layout in the cultural corridor of Hangzhou Matrix Medical Technology Co., Ltd.

General Manager Ji Peihong stated in the introduction that Hangzhou Matrix Medical Technology Co., Ltd. adheres to the concept of "intervention without implantation", develops new interventional medical devices, and takes solving clinical pain points as the first starting point, truly providing new solutions for cardiovascular interventional treatment patients. Subsequently, Vice Governor Wang Wenxu and his delegation visited the R&D laboratory of Hangzhou Juzheng Medical Technology Co., Ltd. and gained a deep understanding of the achievements of the R&D products. General Manager Ji Peihong provided a detailed introduction to the working principle, treatment effect, and market situation of the R&D products to the leaders.

Finally, the leaders affirmed and supported the achievements of Hangzhou Matrix Medical Technology Co., Ltd. in their work, and wished the project success. They hoped that Juzheng would continue to uphold the concept of "intervention without implantation", actively promote the research and development of innovative technologies, make greater contributions to the health of patients undergoing cardiovascular intervention therapy, and further promote the development of the field of vascular intervention therapy.